Morphine Can Protect The Brains Of People Suffering From HIV Infection.
The anaesthetic morphine may relief care for against HIV-associated dementia, says a imaginative study 4rxbox com. Georgetown University Medical Center researchers found that morphine protected rat neurons from HIV toxicity, a origination that could manage to the development of new drugs to treat kinsfolk with HIV-related dementia, which causes depression, anxiety and physical and barmy problems.
So "We believe that morphine may be neuroprotective in a subset of individuals infected with HIV," lead investigator Italo Mocchetti, a professor of neuroscience, said in a Georgetown information release. He and his colleagues conducted the den because they knew that some people with HIV who are heroin users never bare HIV brain dementia. Morphine is like to heroin.
In their tests on rats, the researchers found that morphine triggers imagination cells called astrocytes to produce a protein called CCL5, which activates factors that censor HIV infection in exempt cells. CCL5 "is known to be important in blood, but we didn't identify it is secreted in the brain," Mocchetti said. "Our premise is that it is in the brain to prevent neurons from dying".
The read was to be presented at the annual meeting of the Society of NeuroImmune Pharmacology, April 13 to 17 in Manhattan Beach, Calif. "Ideally, we can use this news to strengthen a morphine-like compound that does not have the typical dependency and clearance issues that morphine has," Mocchetti said.
Showing posts with label cells. Show all posts
Showing posts with label cells. Show all posts
Sunday, January 5, 2014
Friday, November 22, 2013
The New Role Of Stem Cells For Treatment Of Neoplastic Diseases
The New Role Of Stem Cells For Treatment Of Neoplastic Diseases.
For keen myeloid leukemia patients, overactive genes in their leukemic trunk cells (LSC) can turn into a more uncompromising struggle to drub their disease and achieve prolonged remission, new research reveals. "In many cancers, individual subpopulations of cells appear to be uniquely skilled of initiating and maintaining tumors," the study authors explained in their report prices. The researchers identified 52 LSC genes that, when effectively active, appear to keen worse outcomes to each acute myeloid leukemia (AML) patients.
The decree is reported in the Dec 22/29 2010 issue of the Journal of the American Medical Association. Between 2005 and 2007, investigate novelist Andrew J Gentles, of Stanford University in Palo Alto, California, and colleagues examined gene undertaking in a set apart of AML patients as well as healthy individuals. Separate matter concerning AML tumors in four groups of patients (totaling more than 1000) was also analyzed.
In one of the unswerving groups, the investigators found that higher endeavour levels among 52 LSC genes meant a 78 percent chance of death within a three-year period. This compared with a 57 percent danger of death in the same time assemble for AML patients with lower gene activity among these specific "signature" genes. In another AML patient group, the study team observed that higher gene activity prompted an 81 percent peril for experiencing a disease obstruction over three years, compared with just a 48 percent risk centre of patients with low gene activity.
What's more, Gentles and his colleagues found that higher vocation among these 52 LSC genes predominantly meant a poorer response to chemotherapy treatment and slash remission rates. The authors suggested that by "scoring" the bustle levels of these 52 genes from low to high, clinicians might be able to better foreshadow how well AML patients will respond to therapy.
For keen myeloid leukemia patients, overactive genes in their leukemic trunk cells (LSC) can turn into a more uncompromising struggle to drub their disease and achieve prolonged remission, new research reveals. "In many cancers, individual subpopulations of cells appear to be uniquely skilled of initiating and maintaining tumors," the study authors explained in their report prices. The researchers identified 52 LSC genes that, when effectively active, appear to keen worse outcomes to each acute myeloid leukemia (AML) patients.
The decree is reported in the Dec 22/29 2010 issue of the Journal of the American Medical Association. Between 2005 and 2007, investigate novelist Andrew J Gentles, of Stanford University in Palo Alto, California, and colleagues examined gene undertaking in a set apart of AML patients as well as healthy individuals. Separate matter concerning AML tumors in four groups of patients (totaling more than 1000) was also analyzed.
In one of the unswerving groups, the investigators found that higher endeavour levels among 52 LSC genes meant a 78 percent chance of death within a three-year period. This compared with a 57 percent danger of death in the same time assemble for AML patients with lower gene activity among these specific "signature" genes. In another AML patient group, the study team observed that higher gene activity prompted an 81 percent peril for experiencing a disease obstruction over three years, compared with just a 48 percent risk centre of patients with low gene activity.
What's more, Gentles and his colleagues found that higher vocation among these 52 LSC genes predominantly meant a poorer response to chemotherapy treatment and slash remission rates. The authors suggested that by "scoring" the bustle levels of these 52 genes from low to high, clinicians might be able to better foreshadow how well AML patients will respond to therapy.
Monday, September 23, 2013
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved healing prostate cancer vaccine, Provenge, is non-poisonous and has few inconsequential effects, a altered study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy erection. "Provenge was approved based on both protection and clinical data," said guide researcher Dr Simon J Hall, easy chair of urology at Mount Sinai Medical Center in New York City.
This refuge text shows that there are very restrictive philosophy effects, Hall added. The advantage of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer faction junk than chemotherapy, which is the only other treatment option for these patients, Hall explained. In addition, Provenge has improved survival over chemotherapy, he added.
The common survival spell for men given Provenge is 4,5 months, although some patients saying their lives extended by two to three years. "This is a newly present treatment, with very restricted side effects, compared to anything else that a man would be inasmuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual meet in San Francisco.
Data from four look 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved mark of fixation and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do operate activities without any restrictions, the researchers noted.
The newly approved healing prostate cancer vaccine, Provenge, is non-poisonous and has few inconsequential effects, a altered study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy erection. "Provenge was approved based on both protection and clinical data," said guide researcher Dr Simon J Hall, easy chair of urology at Mount Sinai Medical Center in New York City.
This refuge text shows that there are very restrictive philosophy effects, Hall added. The advantage of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer faction junk than chemotherapy, which is the only other treatment option for these patients, Hall explained. In addition, Provenge has improved survival over chemotherapy, he added.
The common survival spell for men given Provenge is 4,5 months, although some patients saying their lives extended by two to three years. "This is a newly present treatment, with very restricted side effects, compared to anything else that a man would be inasmuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual meet in San Francisco.
Data from four look 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved mark of fixation and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do operate activities without any restrictions, the researchers noted.
Subscribe to:
Posts (Atom)